secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001193125-23-075191
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical appoints Cary Vance to Board of Directors, effective April 1, 2023
--------------------------------------------------------------------------------

- Cary Vance appointed as non-executive director, effective April 1, 2023, serving until 2023 Annual Meeting.
- Compensation: $70,000 annual cash, initial $210,000 stock grant (30% options, 70% RSUs), and $105,000 annual equity, subject to shareholder approval.
- Vance has over 25 years healthcare leadership, currently President/CEO of Titan Medical; prior roles include Hansen Medical, Covidien, and GE Healthcare.
- Board determined Vance meets independence standards; no material relationships or arrangements with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312523075191/0001193125-23-075191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312523075191/d467079d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-075191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer